Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02007252 · ClinicalTrials.gov registry record · Phase 2
ACZ885 for the Treatment of Abdominal Aortic Aneurysm
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT02007252 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT02007252, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aortic aneurysms. The design of this study addressed the primary objective of evaluating the change in aneurysmal size in subjects with AAA as a result of treatment with ACZ885.
Interventions
- DRUG Placebo
- DRUG ACZ885
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02007252
The ClinicalTrials.gov registry entry for NCT02007252 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02007252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02007252 about?
NCT02007252 is a clinical study titled "ACZ885 for the Treatment of Abdominal Aortic Aneurysm". This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aort...
What is the current status of trial NCT02007252?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2013-12. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02007252?
The interventions under investigation include: Placebo (DRUG), ACZ885 (DRUG).
Who is sponsoring clinical trial NCT02007252?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.